

# CITATION REPORT

List of articles citing

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel

DOI: 10.1097/00007691-199512000-00017  
Therapeutic Drug Monitoring, 1995, 17, 642-54.

**Source:** <https://exaly.com/paper-pdf/25635345/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
214	The use of therapeutic drug monitoring to optimise immunosuppressive therapy. <b>1996</b> , 30, 107-40		50
213	Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. <b>1996</b> , 42, 1316-1321		55
212	Monitoring new immunosuppressive agents. Are the methods adequate?. <b>1997</b> , 14, 5-15		13
211	Monitoring of cyclosporin and azathioprine in organ transplantation. <b>1997</b> , 14, 17-31		3
210	[Not Available]. <b>1997</b> , 7, 175-97		18
209	Target concentration strategy for cyclosporin monitoring. <b>1997</b> , 32, 175-9		11
208	Whole blood cyclosporin monitoring in liver and heart transplant patients: evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique. <b>1997</b> , 15, 957-63		10
207	The EMIT Cyclosporine Assay: development of application protocols for the Boehringer Mannheim Hitachi 911 and 917 analyzers. <b>1997</b> , 30, 155-62		12
206	Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. <b>1998</b> , 31, 309-16		114
205	Parent cyclosporine in whole blood by monoclonal fluorescence polarization immunoassay for axsym and monoclonal enzyme-multiplied immunoassay for cobas-fara. <b>1998</b> , 31, 681-5		1
204	Conversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A. <b>1998</b> , 12, 337-42		4
203	Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. <b>1998</b> , 705, 289-94		35
202	Suivi thérapeutique des immunosuppresseurs: données actuelles. <b>1998</b> , 1998, 75-82		
201	Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). <b>1998</b> , 30, 1645-9		67
200	Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments. <b>1998</b> , 30, 4045-7		10
199	Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. <b>1998</b> , 44, 2158-2164		97
198	Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. <b>1998</b> , 44, 381-387		29

197	FPIA and EMIT Methods Compared for Cyclosporine Monitoring in Heart Transplant Patients. <b>1998</b> , 44, 693-694		2
196	Evaluation of the New AxSYM Cyclosporine Assay: Comparison with TDx Monoclonal Whole Blood and Emit Cyclosporine Assays. <b>1999</b> , 45, 432-435		24
195	Inhibition of Stimulated Interleukin-2 Production in Whole Blood: A Practical Measure of Cyclosporine Effect. <b>1999</b> , 45, 1477-1484		86
194	Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific?. <b>1999</b> , 45, 371-381		124
193	Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. <b>1999</b> , 3, 225-30		14
192	Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry. <b>1999</b> , 721, 285-94		53
191	Therapeutic drug monitoring of immunosuppressant drugs. <b>1999</b> , 47, 339-50		53
190	Delivering quality for the measurement of immunosuppressive drugs: current performance and future needs. <b>1999</b> , 4, 427-430		4
189	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. <b>1999</b> , 21, 1632-52; discussion 1631		89
188	Generic drugs: the Canadian perspective. <b>1999</b> , 31, 16S-18S		2
187	Generic immunosuppressants: the European perspective. <b>1999</b> , 31, 19S-22S		3
186	Population pharmacokinetics of cyclosporine in kidney transplant patients. <b>1999</b> , 31, 2246-7		6
185	Comparison of cyclosporine immunoassays (AxSYM and RIA) for assessing pharmacokinetic parameters in liver transplant patients. <b>1999</b> , 31, 2421-2		3
184	Advancing the art of immunosuppression with the science of pharmacology. <b>2000</b> , 5, 255-262		4
183	Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 594-8	3-2	37
182	Considerable lack of agreement between S-FPIA and EMIT cyclosporine assay in therapeutic drug monitoring, of heart transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 712-5	3-2	2
181	Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. <b>2000</b> , 33, 383-6		13
180	Mini-review: therapeutic drug monitoring in pediatrics. <b>2000</b> , 33, 333-5		9

179	Minor immunophilin binding of tacrolimus and sirolimus metabolites. <b>2000</b> , 33, 1-6		8
178	Biochemical characterization of the minor immunophilins. <b>2000</b> , 33, 81-7		3
177	Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. <b>2000</b> , 748, 41-53		143
176	High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients. <b>2000</b> , 749, 93-100		18
175	The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. <b>2000</b> , 129, 485-92		19
174	Comparison of the fluorescent polarization (TDx) and the enzymatic competitive (EMIT 2000) immune assays for the measurement of cyclosporin A blood concentration. <b>2000</b> , 55, 207-12		9
173	Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. <b>2000</b> , 114, 536-43		23
172	Cyclosporin A: Vergleichende Untersuchungen mit vier verschiedenen automatisierbaren monoklonalen Immunoassays zur Therapiekontrolle nach Nieren-, Knochenmark-, Herz-/Lungen- und Lebertransplantation. Cyclosporin A: Comparison of Four Automated Monoclonal Immunoassays in Patients after Kidney, Bone Marrow, Heart/Lung, and Liver Transplantation. <b>2000</b> , 114, 536-43		23
171	IS 3-HOUR CYCLOSPORINE BLOOD LEVEL SUPERIOR TO TROUGH LEVEL IN EARLY POST-RENAL TRANSPLANTATION PERIOD?. <i>Journal of Urology</i> , <b>2000</b> , 163, 37-41	2.5	18
170	Recent advances in therapeutic monitoring of cyclosporine: Absorption profiling. <b>2001</b> , 15, 142-155		4
169	Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods. <b>2001</b> , 310, 165-71		24
168	Provision of laboratory services for heart and lung transplantation in Australia. <b>2001</b> , 313, 221-9		1
167	Cyclosporine therapeutic drug monitoring. <b>2001</b> , 33, 3003-5		10
166	Cyclosporine A: peak or trough level monitoring in renal transplant recipients?. <b>2001</b> , 33, 3122-3		2
165	Mycophenolic acid plasma concentrations: influence of comedication. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 35-8	3.2	66
164	Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 100-14	3.2	101
163	Optimized analytical method for cyclosporin A by high-performance liquid chromatography-electrospray ionization mass spectrometry. <b>2001</b> , 754, 201-7		17
162	Pharmacokinetic studies of cyclosporine in Oriental kidney transplantation patients. <b>2001</b> , 6, 236-242		

161	High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood. <b>2001</b> , 15, 898-907		75
160	Cyclosporin Measurement [Who cares about inaccuracy?]. <b>2001</b> , 6, 405-408		10
159	New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. <b>2001</b> , 34, 9-16		125
158	Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. <b>2002</b> , 302, 1123-8		31
157	Principles and Practice of Monitoring Immunosuppressive Drugs/Grundsätze und Praxis beim Monitoring von Immunsuppressiva. <b>2002</b> , 26, 27-36		1
156	Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. <b>2002</b> , 17, 1310-7		37
155	Transport activity and surface expression of the Na <sup>+</sup> -Ca <sup>2+</sup> exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833. <b>2002</b> , 277, 2505-10		14
154	Factors influencing cyclosporine blood concentration-dose ratio. <b>2002</b> , 36, 193-9		11
153	Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 40-6	3.2	73
152	Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 677-88	3.2	23
151	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 59-67	3.2	70
150	Cyclosporin monitoring in Australasia: survey of laboratory practices in 2000. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 471-8	3.2	11
149	Simultaneous and rapid analysis of cyclosporin A and creatinine in finger prick blood samples using liquid chromatography tandem mass spectrometry and its application in C2 monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 757-67	3.2	40
148	Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 479-86	3.2	71
147	Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. <b>2002</b> , 74, 1522-8		22
146	Monitoring mycophenolic acid. <b>2002</b> , 39, 173-83		49
145	Relationship between cyclosporine concentrations obtained using the Roche Cobas Integra and Abbott TDx monoclonal immunoassays in pre-dose and two hour post-dose blood samples from kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 785-8	3.2	6
144	Cyclosporin: revisions in monitoring guidelines and review of current analytical methods. <b>2002</b> , 39, 424-35		33

143	Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. <b>2002</b> , 41, 71-80	49
142	Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. <b>2002</b> , 41, 115-35	66
141	A Positive Drug Test in the Pain Management Patient: Deception or Herbal Cross-Reactivity?. <b>2002</b> , 48, 958-960	6
140	Rapid Liquid Chromatography-Tandem Mass Spectrometry Method for Routine Analysis of Cyclosporin A Over an Extended Concentration Range. <b>2002</b> , 48, 69-76	64
139	Rapid Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood. <b>2002</b> , 48, 955-958	177
138	Evaluation of a No-Pretreatment Cyclosporin A Assay on the Dade Behring Dimension RxL Clinical Chemistry Analyzer. <b>2002</b> , 48, 1059-1065	25
137	Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. <b>2002</b> , 2, 546-50	19
136	Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome?. <b>2002</b> , 16 Suppl 7, 45-8	4
135	A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. <b>2002</b> , 6, 313-8	19
134	Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. <b>2002</b> , 147, 122-9	31
133	Evaluation of essential parameters in the chromatographic determination of cyclosporin A and metabolites using a D-optimal design. <b>2002</b> , 30, 1263-76	12
132	Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. <b>2002</b> , 15, 649-654	15
131	Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. <b>2003</b> , 58, 813-20	26
130	Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks. <b>2003</b> , 50, 442-8	27
129	Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. <b>2003</b> , 492, 133-145	29
128	Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients. <b>2003</b> , 7, 102-10	5
127	Simple determination of cyclosporine in human whole blood by high-performance liquid chromatography. <b>2003</b> , 795, 209-14	11
126	Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. <b>2003</b> , 47, 549-54	7

125	Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients. <b>2003</b> , 35, 1298-9		3
124	Cytotoxicity assessment of three therapeutic agents, cyclosporin-A, cisplatin and doxorubicin, with the ciliated protozoan <i>Tetrahymena pyriformis</i> . <b>2003</b> , 154, 375-85		22
123	Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. <b>2003</b> , 348, 2323-8		96
122	Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 28-35	3.2	29
121	Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 167-73	3.2	48
120	A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. <b>2003</b> , 18, 1201-8		47
119	Cyclosporin A: a new drug in the field of canine dermatology. <b>2004</b> , 15, 61-74		70
118	Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. <b>2004</b> , 27, 231-8		46
117	Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period. <b>2004</b> , 19, 667-71		8
116	Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. <b>2004</b> , 805, 13-20		29
115	Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. <b>2004</b> , 37, 424-8		18
114	Comparison of cyclosporine concentrations in renal transplant recipients using ACMIA and mFPIA methods. <b>2004</b> , 37, 1016-21		4
113	An economic model of 2-hour post-dose cyclosporin monitoring in renal transplantation. <b>2004</b> , 22, 621-32		8
112	Monitoring immunosuppressive drugs. <b>2004</b> , 273-296		1
111	Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. <b>2004</b> , 346, 181-90		106
110	Therapeutic drug monitoring of cyclosporine. <b>2004</b> , 36, 396S-403S		52
109	Experience with cyclosporine. <b>2004</b> , 36, 285S-290S		
108	Cyclosporine in thoracic organ transplantation. <b>2004</b> , 36, 302S-308S		13

107	Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience. <b>2004</b> , 36, 414S-419S	4
106	Patient management by cyclosporine C2 monitoring. <b>2004</b> , 77, 323-4	5
105	Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 215-9	3.2 71
104	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 600-8	3.2 58
103	Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 23-30	3.2 69
102	Monitoring cyclosporine of pre-dose and post-dose samples using nonextraction homogeneous immunoassay. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 58-67	3.2 5
101	Monitoring immunosuppressive drugs: has it a future?. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 244-7	3.2 6
100	Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 315-21	3.2 30
99	CEDIA sirolimus assay compared with HPLC-MS/MS and HPLC-UV in transplant recipient specimens. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 309-14	3.2 15
98	Seeking optimal prescription of cyclosporine ME. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 3-6	3.2 9
97	Evaluation of the immunotech cyclosporine direct radioimmunoassay for the determination of whole-blood cyclosporine in renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 90-3	3.2
96	Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation. <b>2005</b> , 19, 335-9	3
95	Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. <b>2005</b> , 59, 18-27	21
94	A role for cytokine measurement in therapeutic monitoring of immunosuppressive drugs following lung transplantation. <b>2005</b> , 139, 176-8	27
93	Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. <b>2005</b> , 5, 405-430	20
92	Liquid chromatographic-electrospray mass spectrometric determination of cyclosporin A in human plasma. <b>2005</b> , 382, 223-30	10
91	Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?. <b>2005</b> , 39, 119-27	24
90	Clinical Immunosuppression using the Calcineurin-Inhibitors Cyclosporin and Tacrolimus. <b>2005</b> , 321-359	7

89	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. <b>2005</b> , 355, 153-64		15
88	Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection. <b>2005</b> , 37, 871-4		3
87	The V-twin system (Dade Behring Laboratories): a useful tool for immunosuppressive drug monitoring. <b>2005</b> , 37, 167-71		4
86	Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation. <b>2005</b> , 37, 3354-7		5
85	Chronopharmacokinetics of ciclosporin and tacrolimus. <b>2006</b> , 45, 775-88		31
84	12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 721-26	3.2	12
83	Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays. <b>2006</b> , 98, 569-74		7
82	Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 750-7	3.2	20
81	Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 96-102	3.2	35
80	A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. <b>2007</b> , 2, 244-8		18
79	Comparison of three methods for cyclosporine therapeutic monitoring. <b>2007</b> , 39, 2557-9		6
78	Therapeutic Drug Monitoring of Kidney Transplant Recipients Using Profiled Support Vector Machines. <b>2007</b> , 37, 359-372		6
77	Automated monitoring of C2 and C0 blood levels of mycophenolic acid and cyclosporine on the Abbott Architect c8000. <b>2007</b> , 40, 1163-7		7
76	The CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring. <b>2007</b> , 12 Suppl 1, S57-65		4
75	Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography-electrospray mass spectrometry. <b>2008</b> , 41, 728-35		49
74	Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. <b>2008</b> , 41, 910-3		36
73	An in vitro system for the determination of individualized immunosuppression. <b>2008</b> , 40, 918-20		4
72	Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral. <b>2008</b> , 40, 2252-7		6

71	A high-performance liquid chromatography-mass spectrometry method using a novel atmospheric pressure chemical ionization approach for the rapid simultaneous measurement of tacrolimus and cyclosporin in whole blood. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 292-300	3.2	22
70	Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. <b>2009</b> , 39, 931-8		19
69	Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells. <b>2010</b> , 77, 607-13		19
68	Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. <b>2010</b> , 43, 910-20		30
67	Performance evaluation of the new ADVIA Centaur system cyclosporine assay (single-step extraction). <b>2010</b> , 411, 806-11		11
66	Caractéristiques immuno-analytiques de la ciclosporine. <b>2011</b> , 26, 190-193		
65	Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. <b>2011</b> , 31, 574-84		5
64	Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. <b>2011</b> , 67, 601-12		15
63	Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry. <b>2012</b> , 323-348		2
62	Therapeutic monitoring of immunotherapies in autoimmune diseases. <b>2012</b> , 18, 4550-5		3
61	Immunosuppressant medication in cardiac transplant patients - between therapeutic benefit and iatrogenic pathology. <b>2012</b> , 18, 101-111		
60	Simultaneous measurement of cyclosporin A and tacrolimus from dried blood spots by ultra high performance liquid chromatography tandem mass spectrometry. <b>2012</b> , 883-884, 102-7		46
59	Therapeutic drug monitoring and LC-MS/MS. <b>2012</b> , 883-884, 33-49		97
58	Estimation of Abbreviated Cyclosporine A Area under the Concentration-Time Curve in Allogenic Stem Cell Transplantation after Oral Administration. <b>2012</b> , 2012, 342701		7
57	Immunosuppressive drugs, immunophilins, and functional expression of NCX isoforms. <b>2013</b> , 961, 275-87		2
56	Therapeutic drug monitoring of ciclosporin A and tacrolimus in heart lung transplant patients using dried blood spots. <b>2014</b> , 51, 106-9		27
55	Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. <b>2014</b> , 78, 836-46		13
54	Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 433-41	3.2	22

53	Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 640-50	3.2	19
52	Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen. <b>2014</b> , 38,		1
51	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <b>2014</b> , 47, 1069-77		26
50	Recommendations for the frequency of ordering laboratory testing. <b>2015</b> , 38,		
49	Overview of Therapeutic Drug Monitoring. <b>2016</b> , 1-15		3
48	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S80-92	3.2	5
47	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
46	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 170-89	3.2	65
45	Recent advances in therapeutic drug monitoring of immunosuppressive drugs. <b>2016</b> , 79, 257-268		31
44	Therapeutic drug monitoring - Key to personalized pharmacotherapy. <b>2017</b> , 50, 375-379		9
43	Simultaneous determination of cyclosporine and tacrolimus in human whole blood by ultra-high performance liquid chromatography tandem mass spectrometry and comparison with a chemiluminescence microparticle immunoassay. <b>2018</b> , 1087-1088, 36-42		9
42	Sensitive Rapid Fluorescence Polarization Immunoassay for Free Mycophenolic Acid Determination in Human Serum and Plasma. <b>2018</b> , 90, 5459-5465		18
41	Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. <b>2018</b> , 10, 81-94		50
40	Laboratory Support. <b>2018</b> , 197-217		
39	Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 59-68	3.2	3
38	Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometry for Cyclosporine Analysis in Human Whole Blood and Comparison With an Antibody-Conjugated Magnetic Immunoassay. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 69-75	3.2	5
37	Establishing a Hematopoietic Stem Cell Transplantation Unit. <b>2018</b> ,		1
36	Dose Optimization Based on Population Pharmacokinetic Modeling of High-Dose Cyclosporine, a P-glycoprotein Inhibitor, in Combination with Systemic Chemotherapy in Pediatric Patients with Retinoblastoma. <b>2018</b> , 34, 647-655		3

35	Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress. <b>2019</b> , 317, F683-F694		5
34	Assessing immunosuppressive drug concentrations in clinical practice. <b>2020</b> , 7, 277-290		
33	Therapeutic drug monitoring. <b>2020</b> , 905-916		1
32	Using ISO/TS 20914:2019 to calculate the measurement uncertainty of immunosuppressive drugs in a clinical laboratory. <b>2020</b> , 80, 309-312		0
31	Validation of a novel UPLC-HRMS method for human whole-blood cyclosporine and comparison with a CMIA immunoassay. <b>2021</b> , 21, 191		
30	Immunosuppressive Drugs. <b>2008</b> , 165-199		3
29	Pharmacodynamic monitoring of immunosuppressive drugs. <b>1998</b> , 44, 428-432		44
28	Quality assessment issues of new immunosuppressive drugs and experimental experience. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 362-7	3.2	20
27	Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 140-5	3.2	13
26	Tacrolimus quality assessment. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 243	3.2	2
25	Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 277-80	3.2	14
24	Survey of cyclosporine therapeutic ranges, assay methodology, and use of comparing agents in Australasian transplant centers. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 650-6	3.2	11
23	A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 294-300	3.2	35
22	The monitoring of immunosuppressive drugs: a pharmacodynamic approach. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 459-63	3.2	35
21	LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 116-22	3.2	37
20	Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 160-2	3.2	20
19	Recommendations for bioequivalence testing of cyclosporine generics revisited. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 330-45	3.2	26
18	Evaluation of the AxSYM monoclonal cyclosporin assay and comparison with radioimmunoassay. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 474-80	3.2	8

17	Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. <b>1999</b> , 68, 55-62		327
16	Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. <b>2000</b> , 69, 488-96		29
15	Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. <b>2001</b> , 12, 828-833		142
14	A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2003</b> , 127, 283-8	5	14
13	Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2003</b> , 127, 19-22	5	51
12	IS 3-HOUR CYCLOSPORINE BLOOD LEVEL SUPERIOR TO TROUGH LEVEL IN EARLY POST-RENAL TRANSPLANTATION PERIOD?. <i>Journal of Urology</i> , <b>2000</b> , 37	2.5	
11	Neural Networks Ensemble for Cyclosporine Concentration Monitoring. <i>Lecture Notes in Computer Science</i> , <b>2001</b> , 706-711	0.9	3
10	Pharmacologic Monitoring of Immunosuppressive Drugs. <b>2001</b> , 43-59		
9	C. <b>2005</b> , 613-652		
8	Methods of Analysis of Drugs and Drug Metabolites. <b>2007</b> , 163-178		
7	Labormessgrößen. <b>2009</b> , 583-1069		
6	Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Pediatric Patients. <i>Korean Journal of Clinical Pharmacy</i> , <b>2018</b> , 28, 24-29	0.2	
5	Therapeutic drug monitoring of immunosuppressants. <b>2020</b> , 317-332		
4	Cyclosporin therapeutic drug monitoring--an established service revisited. <i>Clinical Biochemist Reviews</i> , <b>2003</b> , 24, 33-46	7.3	19
3	A review on therapeutic drug monitoring of immunosuppressant drugs. <i>Iranian Journal of Basic Medical Sciences</i> , <b>2011</b> , 14, 485-98	1.8	28
2	Persistence in complex systems. <i>Physics Reports</i> , <b>2022</b> , 957, 1-73	27.7	1
1	Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS/MS system. <b>2022</b> , 60, 1753-1762		0